12.135 USD
-0.37 (-2.92%)
We assign a fundamental rating of 4 out of 10 to XRAY. XRAY was compared to 185 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of XRAY while its profitability can be described as average. XRAY is valued quite cheap, but it does not seem to be growing. Finally XRAY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year XRAY was profitable.
In the past year XRAY had a positive cash flow from operations.
XRAY had negative earnings in 4 of the past 5 years.
XRAY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
XRAY has a Return On Assets (-15.60%) which is comparable to the rest of the industry.
XRAY has a Return On Equity (-59.68%) which is in line with its industry peers.
The Return On Invested Capital of XRAY (5.04%) is better than 76.22% of its industry peers.
The Average Return On Invested Capital over the past 3 years for XRAY is below the industry average of 8.84%.
The last Return On Invested Capital (5.04%) for XRAY is above the 3 year average (4.11%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.6% | ||
| ROE | -59.68% | ||
| ROIC | 5.04% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
1.3 Margins
With a decent Operating Margin value of 7.48%, XRAY is doing good in the industry, outperforming 74.59% of the companies in the same industry.
In the last couple of years the Operating Margin of XRAY has declined.
With a Gross Margin value of 51.10%, XRAY perfoms like the industry average, outperforming 45.95% of the companies in the same industry.
XRAY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.48% | ||
| PM (TTM) | N/A | ||
| GM | 51.1% |
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
2. Health
2.1 Basic Checks
XRAY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
XRAY has less shares outstanding than it did 1 year ago.
The number of shares outstanding for XRAY has been reduced compared to 5 years ago.
The debt/assets ratio for XRAY is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.96, we must say that XRAY is in the distress zone and has some risk of bankruptcy.
XRAY's Altman-Z score of 0.96 is in line compared to the rest of the industry. XRAY outperforms 49.73% of its industry peers.
XRAY has a debt to FCF ratio of 29.94. This is a negative value and a sign of low solvency as XRAY would need 29.94 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 29.94, XRAY is doing good in the industry, outperforming 68.65% of the companies in the same industry.
A Debt/Equity ratio of 1.36 is on the high side and indicates that XRAY has dependencies on debt financing.
With a Debt to Equity ratio value of 1.36, XRAY is not doing good in the industry: 77.84% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.36 | ||
| Debt/FCF | 29.94 | ||
| Altman-Z | 0.96 |
ROIC/WACC0.56
WACC9.02%
2.3 Liquidity
A Current Ratio of 1.47 indicates that XRAY should not have too much problems paying its short term obligations.
The Current ratio of XRAY (1.47) is worse than 75.14% of its industry peers.
A Quick Ratio of 0.99 indicates that XRAY may have some problems paying its short term obligations.
XRAY has a worse Quick ratio (0.99) than 75.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
The earnings per share for XRAY have decreased strongly by -14.59% in the last year.
The Earnings Per Share has been decreasing by -7.38% on average over the past years.
The Revenue has decreased by -7.08% in the past year.
The Revenue has been decreasing by -1.17% on average over the past years.
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%
3.2 Future
The Earnings Per Share is expected to grow by 7.40% on average over the next years.
Based on estimates for the next years, XRAY will show a small growth in Revenue. The Revenue will grow by 1.34% on average per year.
EPS Next Y-2.07%
EPS Next 2Y-2.16%
EPS Next 3Y2.63%
EPS Next 5Y7.4%
Revenue Next Year-4.33%
Revenue Next 2Y-1.82%
Revenue Next 3Y-0.42%
Revenue Next 5Y1.34%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 7.68, which indicates a rather cheap valuation of XRAY.
XRAY's Price/Earnings ratio is rather cheap when compared to the industry. XRAY is cheaper than 96.76% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.25. XRAY is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 7.59, the valuation of XRAY can be described as very cheap.
Based on the Price/Forward Earnings ratio, XRAY is valued cheaper than 97.84% of the companies in the same industry.
XRAY is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.98, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.68 | ||
| Fwd PE | 7.59 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 96.22% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, XRAY is valued a bit cheaper than the industry average as 79.46% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 30.27 | ||
| EV/EBITDA | 7.32 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.16%
EPS Next 3Y2.63%
5. Dividend
5.1 Amount
XRAY has a Yearly Dividend Yield of 5.17%, which is a nice return.
XRAY's Dividend Yield is rather good when compared to the industry average which is at 0.19. XRAY pays more dividend than 100.00% of the companies in the same industry.
XRAY's Dividend Yield is rather good when compared to the S&P500 average which is at 1.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.17% |
5.2 History
On average, the dividend of XRAY grows each year by 11.21%, which is quite nice.
XRAY has paid a dividend for at least 10 years, which is a reliable track record.
XRAY has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)11.21%
Div Incr Years6
Div Non Decr Years30
5.3 Sustainability
XRAY has negative earnings and hence a negative payout ratio. The dividend may be in danger.
The dividend of XRAY is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP-14.4%
EPS Next 2Y-2.16%
EPS Next 3Y2.63%
NASDAQ:XRAY (1/13/2026, 2:04:08 PM)
12.135
-0.37 (-2.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners107.4%
Inst Owner Change-0.08%
Ins Owners0.24%
Ins Owner Change-3.15%
Market Cap2.42B
Revenue(TTM)3.62B
Net Income(TTM)-882.00M
Analysts68.18
Price Target12.79 (5.4%)
Short Float %6.14%
Short Ratio3.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.17% |
Yearly Dividend0.62
Dividend Growth(5Y)11.21%
DP-14.4%
Div Incr Years6
Div Non Decr Years30
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.77%
Min EPS beat(2)-19.03%
Max EPS beat(2)1.49%
EPS beat(4)2
Avg EPS beat(4)-3.17%
Min EPS beat(4)-40.52%
Max EPS beat(4)45.37%
EPS beat(8)3
Avg EPS beat(8)-1.68%
EPS beat(12)6
Avg EPS beat(12)4.59%
EPS beat(16)7
Avg EPS beat(16)1.99%
Revenue beat(2)0
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-1.67%
Max Revenue beat(2)-1.16%
Revenue beat(4)1
Avg Revenue beat(4)-1.42%
Min Revenue beat(4)-3.62%
Max Revenue beat(4)0.77%
Revenue beat(8)2
Avg Revenue beat(8)-1.44%
Revenue beat(12)5
Avg Revenue beat(12)-0.9%
Revenue beat(16)5
Avg Revenue beat(16)-2.02%
PT rev (1m)-1.53%
PT rev (3m)-24.6%
EPS NQ rev (1m)-0.64%
EPS NQ rev (3m)-42.56%
EPS NY rev (1m)-0.1%
EPS NY rev (3m)-15.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.3%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.68 | ||
| Fwd PE | 7.59 | ||
| P/S | 0.67 | ||
| P/FCF | 30.27 | ||
| P/OCF | 10.96 | ||
| P/B | 1.64 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.32 |
EPS(TTM)1.58
EY13.02%
EPS(NY)1.6
Fwd EY13.17%
FCF(TTM)0.4
FCFY3.3%
OCF(TTM)1.11
OCFY9.13%
SpS18.16
BVpS7.41
TBVpS-4.29
PEG (NY)N/A
PEG (5Y)N/A
Graham Number16.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.6% | ||
| ROE | -59.68% | ||
| ROCE | 6.38% | ||
| ROIC | 5.04% | ||
| ROICexc | 5.51% | ||
| ROICexgc | 13.81% | ||
| OM | 7.48% | ||
| PM (TTM) | N/A | ||
| GM | 51.1% | ||
| FCFM | 2.21% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
ROICexc(3y)4.36%
ROICexc(5y)4.5%
ROICexgc(3y)15.64%
ROICexgc(5y)20.94%
ROCE(3y)5.38%
ROCE(5y)5.49%
ROICexgc growth 3Y-31.16%
ROICexgc growth 5Y-12.42%
ROICexc growth 3Y-13.44%
ROICexc growth 5Y-4.44%
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
F-Score4
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.36 | ||
| Debt/FCF | 29.94 | ||
| Debt/EBITDA | 3.26 | ||
| Cap/Depr | 40.63% | ||
| Cap/Sales | 3.89% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 35.76% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 0.96 |
F-Score4
WACC9.02%
ROIC/WACC0.56
Cap/Depr(3y)46.81%
Cap/Depr(5y)41.51%
Cap/Sales(3y)4.1%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
EPS Next Y-2.07%
EPS Next 2Y-2.16%
EPS Next 3Y2.63%
EPS Next 5Y7.4%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%
Revenue Next Year-4.33%
Revenue Next 2Y-1.82%
Revenue Next 3Y-0.42%
Revenue Next 5Y1.34%
EBIT growth 1Y3.04%
EBIT growth 3Y-28.45%
EBIT growth 5Y-13.75%
EBIT Next Year42.44%
EBIT Next 3Y14.41%
EBIT Next 5Y11.96%
FCF growth 1Y-63.3%
FCF growth 3Y-18.29%
FCF growth 5Y-11.45%
OCF growth 1Y-38.44%
OCF growth 3Y-11.14%
OCF growth 5Y-6.32%
DENTSPLY SIRONA INC / XRAY FAQ
What is the ChartMill fundamental rating of DENTSPLY SIRONA INC (XRAY) stock?
ChartMill assigns a fundamental rating of 4 / 10 to XRAY.
What is the valuation status for XRAY stock?
ChartMill assigns a valuation rating of 7 / 10 to DENTSPLY SIRONA INC (XRAY). This can be considered as Undervalued.
How profitable is DENTSPLY SIRONA INC (XRAY) stock?
DENTSPLY SIRONA INC (XRAY) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for XRAY stock?
The Price/Earnings (PE) ratio for DENTSPLY SIRONA INC (XRAY) is 7.68 and the Price/Book (PB) ratio is 1.64.
Can you provide the dividend sustainability for XRAY stock?
The dividend rating of DENTSPLY SIRONA INC (XRAY) is 7 / 10 and the dividend payout ratio is -14.4%.